The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Valeant Pharmaceuticals International Inc

TSX: VRX
Delayed quote

$122.69

Today's change+6.33 +5.44%
Updated February 12 4:00 PM EST. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

TSX: VRX
Delayed quote

$122.69

Today's change+6.33 +5.44%
Updated February 12 4:00 PM EST. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc up sharply

Valeant Pharmaceuticals International Inc closed up sharply Friday, rallying $6.33 or 5.44% to $122.69. Over the last five days, shares have lost 8.67% and are down 12.71% for the last year to date. This security has underperformed the S&P TSX by 22.72% during the last year.

Key company metrics

  • Trailing P/E49.84×
  • P/E 1 year forward11.82×
  • Forward PEG0.51×
  • Indicated annual dividend--
  • Dividend yield--
  • Trailing EPS$2.46
Updated February 12 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+6.09%

Based on its net profit margin of 6.09%, Valeant Pharmaceuticals International Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX2.43%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue2,7872,7322,1912,280
Total other revenue--------
Total revenue2,7872,7322,1912,280
Gross profit2,1392,0471,6161,690
Total cost of revenue648685575590
Total operating expense2,3392,3911,6681,672
Selling / general / administrative698686574525
Research & development102815659
Depreciation / amortization67958536586
Interest expense (income), net operating--------
Unusual expense (income)18217792406
Other operating expenses, total3017767
Operating income448342523608
Interest income (expense), net non-operating-420-413-298-225
Gain (loss) on sale of assets--------
Other--------
Income before tax-6-65155590
Income after tax52-5275534
Income tax, total-57-138156
Net income50-5374535
Total adjustments to net income--------
Net income before extra. items50-5374535
Minority interest-2-1-11
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items50-5374535
Inc. avail. to common incl. extra. items50-5374535
Diluted net income50-5374535
Dilution adjustment----00
Diluted weighted average shares351344343342
Diluted EPS excluding extraordinary itemsvalue per share0.14-0.150.211.56
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.570.190.342.82